Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review)

Metabolic dysfunctions have been reported in patients diagnosed with severe mental illnesses who are undergoing treatment with antipsychotics, especially second-generation agents. Sodium-glucose co-transporter 2 inhibitors (SGLT2Is) and glucagon-like peptide receptor agonists are new-generation anti...

Descripción completa

Detalles Bibliográficos
Autor principal: Vasiliu, Octavian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947579/
https://www.ncbi.nlm.nih.gov/pubmed/36845949
http://dx.doi.org/10.3892/etm.2023.11824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947579/
https://www.ncbi.nlm.nih.gov/pubmed/36845949
http://dx.doi.org/10.3892/etm.2023.11824

Ejemplares similares